VLS (VLS) Fair Value & Analysis
Healthcare · Market cap A$139M
Fair value as of: Jun 24, 2026
From 24 valuation models · updated 8 days ago
Share price +4.6% over the past month.
Price vs Fair Value (12 months)
12‑month range A$2.04 – A$2.73 · fair‑value band A$3.17 – A$5.28 · the A$2.50 price screens below the A$4.22 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
VLS (VLS) currently trades at A$2.50, while our model-based Fair Value estimate is A$4.22 — implying the stock looks roughly 68.8% undervalued today. We read business quality at 68/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
Over the trailing twelve months, VLS generated revenue of A$93.3M at a net margin of 11.2%. Revenue grew 19.2% year over year. It earns a return on equity of 19.2%. The balance sheet holds a net cash position of A$31.3M. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
VLS reported revenue of A$93.3M in FY2025 versus A$57.1M in FY2021, a compound +13.1%/yr. Reported net income was A$10.4M in FY2025, compounding +5.9%/yr from FY2021.
Is VLS fairly valued? → Check now
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| 1276 1276 | HK$57.85 | HK$29.84 | -48% |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥49.36 | ¥26.59 | -46% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Zoetis Inc Z1TS34 | R$26.19 | R$26.01 | -1% |
| Hansoh Pharmaceutical Group 3692 | HK$29.58 | HK$18.75 | -37% |
| Divi's Laboratories Limited DIVISLAB | ₹6,788 | ₹2,035 | -70% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is VLS (VLS) undervalued?
What is the fair value of VLS?
What is the quality score of VLS?
What is the revenue of VLS (VLS)?
What is the net profit margin of VLS?
Does VLS pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.